VIVEbiotech makes a capital increase of 3.5 million euros to complete its expansion plan
VIVEbiotech has carried out a capital increase of 3.5 million euros to finance its strategic plan, which highlights the construction of three new cleanrooms and the incorporation of new equipment that will multiply its production capacity substantially. VIVEbiotech will now have 600 square meters of clean rooms with 8 nanobioreactors and two large capacity bioreactors.
Thanks to this growth, in 2021 VIVEbiotech will be able to produce lentiviral vectors for advanced clinical trials in which hundreds of patients participate, as well as to attend the commercial scale production of any gene therapy product that uses lentivirus. The trend of the gene therapy market is growing and with the new infrastructure VIVEbiotech will be able to respond to this reality.
The capital increase has been endorsed by VIVEbiotech´s private partners who continue with their commitment to the company and its future. Easo Ventures and Inveready are the new shareholders, the latter being a venture capital fund with extensive experience in biotechnology.
VIVEbiotech is already producing lentiviral vectors for 16 gene therapy projects, 6 of them with CAR-Ts. Customers are located in European countries, the United States, Israel and Australia.
Related news
CIC biomaGUNE launches a company that will transform disease diagnosis by using nanosensors
Taldeki Biosolutions will be developing sensors for rapid, cost-effective, robust antibody detection, thus overcoming the stability and cost problems of current in vitro diagnostics
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
Support the execution of a robust pipeline of customer projects for innovators developing groundbreaking in vivo and ex vivo cell and gene therapies.
CIC nanoGUNE launches a new call: Industry Collaborative Research Positions
Programa honen helburua da ikertzaile profesionalak tokiko erakundeetan sar daitezen erraztea
Companies with greater gender equality perform better in terms of innovation and are more competitive
The study of the SPRI initiative "Women in Industry" shows that gender equality has an impact on the improvement of company results.
SPRI presents the results of the study on the impact of women on industrial competitiveness at the World Manufacturing Forum
The reports is the continuation of the work carried out by the SPRI Group and the Foreign Network office in Milan since 2020 as leader of the Women in Manufacturing expert group.
Europako fabrikazio-ikerketaren etorkizuna
Donostian, egunotan, MANUFUTURE Conference 2023 egiten ari da, hau da, fabrikazio-industriaren etorkizunari buruzko Europako konferentzia.
REBEL TICKETS resale platform, now available on your cell phone
Now you will be able to buy and sell your tickets in a simpler, more comfortable and accessible way.
Basque Open Industry will show Europe its industrial and technological ecosystem at the European SME Week (SME Week) from 13 to 17 November.
Talent, internationalisation, energy-environmental and technology-digital transitions. SME Week 2023. Exhibition and stands at the BEC: “Rebuild Ukraine”.
Aker Solutions selects TUBACEX as a delivery partner for umbilical tubes for key projects on the Norwegian Continental Shelf
An order intake for a sum of more than €70 million is one of the most significant deals in the umbilicals market. Solidifying TUBACEX’s technological position as a supplier of advanced industrial solutions for energy and mobility sectors.
Get to know the assets of the BDIH: 5-axis multi-process milling cell, capable of very high speed operations
The University of the Basque Country offers Basque companies, via the BDIH, the possibility to have at their disposal a 5-axis multi-process milling cell, capable of very high-speed operations.